Seal and logotype of Brandeis University The Heller School logo

Recent Conferences

June 11, 2009

Federal Strategies for Promoting Affordable Biologics: Follow-On Biologic Competition

One proposed strategy for improving the affordability of biologics is creating an FDA approval pathway for “biosimilars.” This is the subject of legislation recently filed by Energy and Commerce Chairman Waxman and a soon to be released Federal Trade Commission report.

This Forum will examine unique science and regulatory questions concerning biosimilars’ interchangeability, potential impact on both market competition and reimbursement strategies, and broad policy consideration concerning the potential economic implications for patients, payers, and product manufacturers.